ulcerative-colitis
(3)
AltruBio Inc.
AltruBio is a clinical-stage San Francisco biotech developing first-in-class immune checkpoint enhancer antibodies for autoimmune and inflammatory diseases. Its lead program, ALTB-268, targets PSGL-1 to restore T-cell homeostasis, and is advancing through mid-stage trials in ulcerative colitis. The company rebranded from AbGenomics in 2020 under CEO Judy Chou and closed an oversubscribed $225M Series B in 2024.
Enthera Pharmaceuticals
Enthera Pharmaceuticals is a clinical-stage biotech based in Milan, Italy, developing first-in-class biologics that aim to do something most autoimmune drugs do not: restore the organ, not just calm the inflammation. Its lead antibody, ebrasodebart (Ent001), blocks the IGFBP3/TMEM219 pathway, a signal that drives apoptosis of intestinal stem cells in the gut and insulin-producing beta cells in the pancreas. The company targets inflammatory bowel disease and type 1 diabetes, two conditions with deep unmet need, and is advancing the program through Phase 1 clinical trials.
Oshi Health
Oshi Health is a virtual-first gastrointestinal care clinic that gives the roughly one in four Americans living with digestive disorders fast access to a coordinated team of GI providers, registered dietitians, behavioral health specialists, and care coordinators. Available in all 50 states as an in-network benefit, Oshi pairs unlimited virtual visits and messaging with evidence-based, whole-person treatment - an approach a national health plan's analysis tied to 92% symptom improvement, 98% patient satisfaction, and more than $10,000 in medical cost savings per patient over six months.